For over a decade, inhibitors of Vascular Endothelial Growth Factor (VEGF) have been the gold standard for treating "wet" age-related macular degeneration (nAMD) and diabetic retinopathy. By neutralizing the signal that triggers leaky, abnormal blood vessel growth, these drugs have saved the sight of millions. However, clinicians have hit a therapeutic ceiling.
A significant portion of patients—estimated between 30% and 40% in conditions like diabetic macular edema by Wenrui Lu and Kunhong Xiao—exhibit a suboptimal response. These "recalcitrant" cases suffer from persistent retinal fluid, frequent relapses, and eventual permanent vision loss due to subretinal fibrosis (scarring). Current research is shifting away from simple VEGF suppression toward multi-modal strategies that address the biological complexity of the resistant eye.
The Limits of Single-Pathway Targeting
The primary reason anti-VEGF therapies fail is biological redundancy. In advanced disease, VEGF is often not the sole driver of vascular leakage. When one pathway is blocked, the body may compensate through alternative signaling axes.
To address this, researchers are developing "bispecific" antibodies that hit two targets simultaneously. Franziska Eckardt and colleagues have demonstrated that switching recalcitrant patients to faricimab—which targets both VEGF and Angiopoietin-2 (Ang-2)—can resolve persistent fluid where standard drugs failed. As shown in Retinal and choroidal efficacy of switching treatment to faricimab in recalcitrant neovascular age related macular degeneration, this dual-pathway approach not only stabilizes the retina but also extends the interval between injections, reducing the "treatment burden" that often leads to patient dropout. Similarly, Yingyi Lu has explored RC28-E, a fusion protein that targets both VEGF and Fibroblast Growth Factor (FGF), aiming to suppress the scarring that VEGF inhibitors alone cannot prevent.
Overcoming Resistance with High-Dose Regimens
In some cases, the "resistance" is not a lack of drug efficacy, but a lack of drug concentration. Some eyes may require a higher "molar dose" to fully neutralize the growth factors present in the vitreous.
Recent clinical evidence suggests that escalating the dose of existing drugs can break through therapeutic plateaus. Michael Hafner and Franziska Eckardt found that increasing aflibercept dosing from 2 mg to 8 mg significantly reduced intraretinal fluid in therapy-resistant nAMD. This "high-dose" strategy, as detailed in Deep learning-assisted analysis of biomarker changes after increase of dosing from aflibercept 2 mg to 8 mg in therapy-resistant neovascular age-related macular degeneration, suggests that many "non-responders" simply require a more potent pharmacological punch to achieve anatomical stability.
Addressing the Pachychoroid and Inflammatory Drivers
Not all neovascularization is created equal. Diseases in the "pachychoroid spectrum"—characterized by an abnormally thick choroid—often show higher resistance to standard anti-VEGF protocols. Nikolaus Luft and Jakob Siedlecki observed that patients with pachychoroid neovasculopathy who failed ranibizumab often responded when switched to aflibercept, likely due to aflibercept's broader affinity for related growth factors like Placental Growth Factor (PlGF).
Furthermore, inflammation and fibrosis are now recognized as parallel drivers of vision loss. Ruoshuang Zhang and Dongxin Lin have shown that inhibiting the COX-2 enzyme can reduce subretinal fibrosis, a complication that anti-VEGF drugs typically ignore. By targeting the inflammatory environment (macrophage infiltration), researchers hope to prevent the "one-two punch" of leakage followed by scarring.
Precision Monitoring and New Molecular Axes
As the toolkit for treating resistant disease expands, the challenge shifts to identifying which patient needs which alternative therapy.
- AI-Driven Diagnostics: Michael Häfner and Ben Asani are using deep learning to quantify subtle anatomical changes—like pigment epithelial detachment (PED) volumes—that are invisible to the naked eye but indicate whether a switch in therapy is working.
- Novel Signaling Pathways: Beyond proteins, researchers are looking at the "dark matter" of the genome. Yingqian Peng has identified transfer RNA-derived small RNAs (tsRNAs) as potential new targets, while Xiao‐Lin Fu and Jianzhi Chen have mapped the miR-192-5p/ELAVL1/PI3Kδ axis as a critical regulator of angiogenesis in diabetic retinopathy.
The transition from "VEGF-only" to "multi-target" and "high-dose" strategies represents a maturation of the field. By acknowledging that the eye's vascular pathology is driven by a complex web of inflammation, mechanical stress, and redundant growth signals, researchers are finally beginning to address the patients who were previously left in the dark.